TechAILatest.newsTrackers
AI Business & Funding / Funding rounds

Isomorphic Labs raises $5 billion Series C, then signs an oncology deal with MSD

Isomorphic Labs raised $5 billion on 17 November 2026 in a round co-led by Greenoaks and Sequoia, then signed a cancer drug research deal with MSD.

By Emre A.Published

Abstract illustration of rising bars and a growth lineTech AI Latest
Illustration of rising bars and a growth line, made by Tech AI Latest for this story. Illustration: Tech AI Latest (Original illustration)

Isomorphic Labs, the Alphabet drug discovery company led by Demis Hassabis, announced a $5 billion Series C on 17 November 2026, co-led by Greenoaks and Sequoia Capital with Andreessen Horowitz joining. It did not disclose a valuation. Two days later Merck, known as MSD outside the US and Canada, signed a research collaboration with the company on a cancer target. Isomorphic has not yet put a drug into human trials.

Key facts

  • Announced: 17 November 2026 (Isomorphic Labs release)
  • Amount: $5 billion Series C, co-led by Greenoaks and Sequoia Capital; Andreessen Horowitz new
  • Returning investors: Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund
  • Valuation: not disclosed by the company
  • 19 November: research deal with MSD on an undisclosed oncology target; upfront payment, milestones and royalties not quantified
  • Clinical status: no human trial or named drug candidate disclosed

What Isomorphic Labs announced

Isomorphic Labs, the London drug discovery company spun out of DeepMind under Alphabet in 2021, announced a $5 billion Series C on Tuesday, 17 November 2026. Greenoaks and Sequoia Capital co-led the round and Andreessen Horowitz joined as a new investor. Existing investors Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund took part, and Alphabet made what the company calls a significant investment. Isomorphic did not state a valuation.

The company says the money will scale IsoDDE, its drug design engine, and its pipeline of AI-designed candidates, and that it will keep developing the engine while moving into new areas of biology. The release quotes Konstantine Buhler of Sequoia, who said the company is building foundational technology for the future of medicine. Demis Hassabis, who also runs Google DeepMind, leads Isomorphic as chief executive.

The round arrives six months after a $2.1 billion Series B in May 2026 led by Thrive Capital, which itself followed a $600 million first external round in 2025, according to Fierce Biotech and Tech Funding News.

The MSD deal two days later

On 19 November, Merck announced a strategic research collaboration with Isomorphic to discover small-molecule drug candidates against an oncology target the companies call strategically important but do not name. Isomorphic runs the computer predictions and delivers molecular designs using IsoDDE and selected proprietary datasets from Merck. Merck, known as MSD outside the US and Canada, takes over preclinical and clinical development, manufacturing and sales.

Isomorphic receives an upfront payment and can earn research, development, regulatory and commercial milestone payments plus tiered royalties on sales. It also holds an option to co-fund development in return for higher royalties. Neither company gave the dollar amounts.

MSD joins Eli Lilly and Novartis, which signed research collaborations with Isomorphic in January 2024. In the 2024 deals Lilly paid $45 million upfront with up to $1.7 billion in milestones, and Novartis paid $37.5 million upfront with up to $1.2 billion, according to the companies at the time.

What changed and why it matters

Isomorphic has now raised $7.1 billion across its Series B and C since May, without a drug in human trials. Tech Times noted that the company disclosed no human trial, no named clinical candidate and no valuation alongside the round, and that its preclinical results in oncology and immunology are described only as positive. Investors are betting on the engine and the partner deals rather than on clinical data.

The round also fits a pattern on this site's funding tracker: the largest November checks are going to companies building or applying frontier models, from Anthropic's IPO to Mirendil's $1 billion Series A. For drug discovery, the comparison is Anthropic's own push, covered in our story on Claude's six drug development partners.

What to watch next

The open question is the clinic. Isomorphic has said it aims to take its first candidates into trials but has given no date or target. Watch for a named candidate, an investigational new drug filing, and the financial terms of the MSD deal if Merck reports them. More coverage is in the AI business hub.

What changed

BeforeIsomorphic Labs had raised a $2.1 billion Series B in May 2026 and had research deals with Eli Lilly and Novartis
After$5 billion more in a Series C co-led by Greenoaks and Sequoia, Andreessen Horowitz as a new investor, and MSD as a new pharma partner on an oncology target
Who it affectsAI drug discovery startups competing for capital and partners; pharma companies weighing AI design deals; investors in Alphabet

Questions people ask

How much did Isomorphic Labs raise?
$5 billion in a Series C announced on 17 November 2026, co-led by Greenoaks and Sequoia Capital.
What is Isomorphic Labs valued at?
The company did not disclose a valuation with the round.
What is the Isomorphic Labs and MSD deal?
A research collaboration announced on 19 November 2026 to design small-molecule drugs for an undisclosed cancer target. Isomorphic gets an upfront payment, milestones and royalties; the amounts were not stated.

Sources

  1. Isomorphic Labs announces $5 Billion Series C funding (Isomorphic Labs via PR Newswire, 17 Nov 2026)
  2. Merck and Isomorphic Labs Enter Strategic Research Collaboration (Merck, 19 Nov 2026)
  3. Isomorphic Labs secures $2.1 Billion funding (Isomorphic Labs, 12 May 2026)
  4. Isomorphic Labs raises $5B series C months after $2.1B round (Fierce Biotech, 17 Nov 2026)
  5. Isomorphic Labs raises $5bn to advance drug pipeline (Pharmaceutical Technology, 17 Nov 2026)
  6. DeepMind spinout Isomorphic Labs lands $5B Series C to take AI-designed medicines into the clinic (Tech Funding News, 17 Nov 2026)
  7. Isomorphic Labs Raises $5 Billion, Discloses No Human Trial (Tech Times, 17 Nov 2026)

Reference pages

Spotted an error? See the corrections policy and tell the editor. Facts in this story come from the sources listed above; vendor claims are attributed.

Comments

Loading comments.

No links, no insults; comments that break the rules are not published. 0/1000